TABLE 1.
Baseline Demographic and Clinical Characteristics
| Characteristic | Group A (n = 12) | Group B (n = 6) | Group C (n = 14) |
| Male | 7 | 4 | 7 |
| Female | 5 | 2 | 7 |
| Age (y) | 53 ± 13 | 55 ± 10 | 50 ± 10 |
| Primary tumor site | |||
| Pancreas | 3 | 3 | 7 |
| Stomach | 1 | 0 | 0 |
| Duodenum | 1 | 1 | 3 |
| Rectum | 2 | 0 | 2 |
| Lung | 1 | 1 | 0 |
| Ovary | 0 | 0 | 0 |
| Carcinoma of unknown primary | 0 | 0 | 1 |
| Multiple endocrine neoplasia | 0 | 1 | 0 |
| Paraganglioma | 2 | 0 | 1 |
| Pheochromocytoma | 2 | 0 | 0 |
| Tumor grade | |||
| 1 | 3 | 1 | 3 |
| 2 | 9 | 4 | 10 |
| 3 | 0 | 1 | 1 |
| Number of lesions | |||
| 1–10 | 4 | 2 | 6 |
| 1–20 | 2 | 2 | 1 |
| >20 | 6 | 2 | 7 |
| Metastases | |||
| Liver | 9 | 5 | 14 |
| Bone | 8 | 2 | 6 |
| Lymph nodes | 7 | 2 | 5 |
| Lung | 2 | 1 | 3 |
| Prior treatment | |||
| Surgery | 9 | 2 | 7 |
| Somatostatin analog | 8 | 5 | 5 |
| Everolimus | 2 | 3 | 1 |
| Tyrosine kinase inhibitor | 1 | 5 | 9 |
| Chemotherapy | 2 | 3 | 6 |
| Radiotherapy | 1 | 1 | 1 |
| Transarterial chemoembolization | 1 | 1 | 3 |
| Disease course (mo) | 58 ± 64 | 58 ± 26 | 55 ± 25 |
Qualitative data are numbers; continuous data are mean ± SD.